Title:
FUSION PROTEIN TARGETING INTERGRIN ALPHA(IIB)BETA3 AND CONTAINING TISSUE PLASMINOGEN ACTIVATOR OR VARIANT THEREOF AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2024/060167
Kind Code:
A1
Abstract:
The present invention provides a fusion protein, which comprises: a tissue plasminogen activator or a variant thereof; a disintegrin or a variant thereof; and a connector. The connector connects the tissue plasminogen activator or the variant thereof, and the disintegrin or the variant thereof, and comprises an amino acid sequence set forth in any one of SEQ ID NOs: 1 to 7. The present invention further provides a method for treating or preventing thrombosis–related diseases by using the described fusion protein.
Inventors:
CHUANG WOEI-JER (CN)
Application Number:
PCT/CN2022/120702
Publication Date:
March 28, 2024
Filing Date:
September 23, 2022
Export Citation:
Assignee:
CHUANG WOEI JER (CN)
International Classes:
C07K19/00; A61K38/16; A61P7/02; C07K7/04; C07K14/46; C07K14/745; C12N9/64
Foreign References:
| CN101155916A | 2008-04-02 | |||
| CN111601816A | 2020-08-28 | |||
| CN103179982A | 2013-06-26 | |||
| US5500411A | 1996-03-19 | |||
| CN103623396A | 2014-03-12 | |||
| CN108430489A | 2018-08-21 | |||
| CN113416724A | 2021-09-21 | |||
| US20200164114A1 | 2020-05-28 | |||
| CN1970746A | 2007-05-30 | |||
| TW201306861A | 2013-02-16 |
Attorney, Agent or Firm:
SHANGHAI YUANTONG LAW FIRM (CN)
Download PDF: